NLRP3 and familial dilated cardiomyopathy: Furthermore, dapagliflozin has been shown to inhibit the activation of the NLRP3 inflammasome by suppressing p38-dependent Toll-like receptor 4 expression and reducing ROS production, highlighting its potential therapeutic value in treating DCM (103).